

## PATENT APPLICATION TRANSMITTAL

The Assistant Commissioner of Patents  
Washington, D.C. 20231

Sir:

**Customer No. 005487**

Transmitted herewith for filing is the patent application  
under 37 CFR 1.53(b) of:

**INVENTORS: Icard-Liepkalns, C., Mallet, J.,  
Ravassard, P.**

FOR: POLYPEPTIDES OF THE "BASIC HELIX-  
LOOP-HELIX" BHLH FAMILY, CORRESPONDING  
NUCLEIC ACID SEQUENCES

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C. 20231, on \_\_\_\_\_.

June 16, 2000  
Date of Deposit  
Debra L. Wetherill  
Signature  
E162018803705  
Express Mail No.

- ☒ If a CONTINUING Application, check appropriate box and supply the requisite information:  
☐ Continuation      ☐ Divisional      ☒ Continuation-in-part  
of prior application no: 09/331,356, filed July 12, 1999, which is a 371 application  
of PCT/FR97/02368 filed December 19, 1997. This application also claims benefit  
of foreign priority under 35 U.S.C. 119(a) to application FR96/15651 filed in France  
on December 19, 1996. application (The cross reference has been/will be inserted on page one  
of the specification).
- ☐ This application claims the benefit of U.S. Provisional Application No. \_\_\_\_\_  
filed \_\_\_\_\_

Enclosed are:

- ☒ Specification [Total Pages 103]
- ☒ 7 Sheets/Pages of Drawing.
- ☒ Nucleotide and/or Amino Acid Sequence Submission:  
☒ Computer Readable Copy ☒ Paper Copy ☒ Statement verifying identity of said copies.
- ☐ A Declaration ☐ Newly Executed (original or copy)  
☐ Copy from a prior application (37 CFR 1.63(d))
- ☐ ***Incorporation By Reference*** (useable if filing a continuation/divisional and a copy of the declaration from the prior application is enclosed.)  
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.
- ☒ Also enclosed:  
Post Card  
⌚Computer Diskette with Sequence Listing/Statement

# PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of  
**Icard-Liepkalns et al.**

Examiner: **Not yet assigned**

Customer No. 005487

Art Unit: **Not yet assigned**

Serial No.: **Not yet assigned**

Filed: **Herewith**

Title: **Polypeptides Of The "Basic Helix-Loop-Helix" BHLH Family, Corresponding Nucleic Acid Sequences**

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C. 20231, on

June 16, 2008  
Date of Deposit

Silvia L. Wetherill  
Signature

EL620188037US  
Express Mail No.

### STATEMENT REGARDING CONTENT OF PAPER AND COMPUTER READABLE COPIES PURSUANT TO 37 C.F.R. 1.821 (f)

Assistant Commissioner for Patents

Washington, D.C. 20231

Sir:

The undersigned states that the content of the nucleotide and/or amino acid sequences set forth in the "Sequence Listing" part of the enclosed patent application required by 37 C.F.R. 1.821 (c) and the computer readable copies required by 37 C.F.R. 1.821 (e) submitted herewith are the same.

Respectfully submitted,

Karen I. Krupen

Karen I. Krupen, Reg. No. 34,647  
Attorney/Agent for Applicant

Aventis Pharmaceuticals Products Inc.  
Patent Department  
Route #202-206 / P.O. Box 6800  
Bridgewater, NJ 08807-0800  
Telephone (908) 231-4658  
Telefax (908) 231-2626

Docket No. ST96042A



- ☐ This application is filed by fewer than all the inventors named in the prior application.
- ☐ DELETE the following inventor(s) named in the prior nonprovisional application:

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

CLAIMS AS FILED					
	(1) FOR	(2) NUMBER FILED	(3) NUMBER EXTRA	(4) RATE	(5) BASIC FEE (\$690.00)
	TOTAL CLAIMS	66 - 20	42	x \$ 18.00	\$756
	INDEPENDENT CLAIMS	11 - 3	8	x \$ 78.00	\$624
	MULTI-DEPENDENT CLAIMS(S), Per Application (\$260.00)				
				TOTAL FILING FEE	\$2070

- ☐ Cancel in this application original claims \_\_\_\_\_ of the prior application before calculating the filing fee. (At least one original independent claim has been retained for filing purposes).
- ☒ Please charge my Deposit Account No. **18-1982** in the amount of \$2070  
A duplicate copy of this sheet is enclosed.
- ☒ The Commissioner is hereby authorized to charge any fees under 37 C.F.R. 1.16 and 1.17 which may be required by this paper, or credit any overpayment to Account No. **18-1982**.  
A duplicate copy of this sheet is enclosed.



Karen I. Krupen, Reg. No. 34,647  
Attorney/Agent for Applicant

Aventis Pharmaceuticals Products Inc.  
Patent Department  
Route #202-206 / P.O. Box 6800  
Bridgewater, NJ 08807-0800  
Telephone (908) 231-4658  
Telefax (908) 231-2626

Docket No. ST96042A